Johnson & Johnson recorded about $7 billion in charges in Q3 2026, including a proposed talc litigation resolution and expenses tied to the Firefly Bio transaction and a Sail Biomedicines collaboration, which weighed heavily on earnings. Despite this, the company raised its full-year revenue and earnings guidance, with quarterly revenue up nearly 6% while GAAP earnings per share fell about 96%. The proposed talc settlement totals $5.5 billion, with an initial $3 billion payment due in 2027 and the remainder paid in later years. The author views the settlement as a net positive that could let J&J focus on long-term growth, noting that healthcare spending tends to hold up in recessions. J&J has increased its dividend for 64 consecutive years, which the author cites as evidence of the company's resilience.
Summary written by Upside AI from the original article. Read the source for full details.
Read the original on Yahoo Finance ↗
Keywords
Johnson & Johnsonpharmaceuticalshealthcaredividendsearnings
Open a keyword to see other news on the same topic.
Related tickers and likely impact
SPY
• NeutralSPDR S&P 500 ETF
Relevance: low
| Market | US stocks |
|---|---|
| Sector | ETF |
| Close on 10/30/2026 | 755.71 |
| Change that session | -1.77% |
Impact is scored by AI from the headline and may be wrong. It is not investment advice.
Related news
- J&J's potential 'game-changer' drug — plus, what Microsoft's mass buyouts mean
J&J reported Phase 1 results for its investigational once-daily oral drug JNJ-6143: 12 of 16 patients with advanced prostate cancer and measurable tumors achieved a complete or partial response, or 75%, and its shares moved higher. Leerink called the results a potential 'game-changer', and J&J could share future development plans at its Dec. 8 Enterprise Business Review. The article also notes Meta's plan to raise up to $95 billion in equity, SpaceX's $40 billion debt raise to finance Nvidia GPU purchases, and Anthropic's IPO filing. Microsoft shares edged higher after it offered voluntary buyouts to about 60,000 eligible employees, which the author sees as a function of optimizing its operating structure rather than a sign of slowing business. Microsoft is expected to generate roughly $8 billion of free cash flow next quarter, versus outflows of $9.9 billion at Amazon and $2.3 billion at Alphabet, according to FactSet.
- Johnson & Johnson Raised Its Dividend Every Year. Why Did It Trail the S&P 500?
Johnson & Johnson (NYSE:JNJ) has raised its dividend for 64 straight years, yet a plain S&P 500 index fund beat the stock over the past decade. A $1,000 investment 10 years ago with reinvested dividends would be worth $2,957.10 today, about $703 of it from dividends, versus $3,593.10 for the S&P 500 over the same period, excluding dividends. In the third quarter of 2026, about $7 billion in charges for a proposed talc settlement and two deals cut reported EPS to $0.09, while adjusted EPS was $2.59. The company expects $21 billion in free cash flow this year, but net debt is about $28 billion, and two recent deals are expected to cut 2027 adjusted EPS by $1.36; the article warns that if talc payments eat into free cash flow, dividend increases could shrink.
- 2 Dividend Stocks Crushing the Market in 2026 (and Which Ones Can Keep Going)
The article examines Johnson & Johnson (JNJ) and Amgen (AMGN), two dividend stocks that have outperformed the market in 2026. For J&J, revenue and earnings beat expectations and guidance was slightly raised, but its medtech unit faces weaker Impella demand and a Class 1 recall in the U.S.; the article still sees long-term prospects intact, citing new drug launches, the OTTAVA surgical system, a proposed $5.5 billion talc settlement and a 64-year dividend increase streak. Amgen's second-quarter revenue rose 10% to $10.1 billion despite FDA moves to remove Tavneos and falling denosumab sales after losing exclusivity. The article says growth drivers such as Tezspire, Tepezza and the MariTide obesity candidate could offset these headwinds.
- Why Johnson & Johnson Stock Dropped Today
Johnson & Johnson shares fell 6.8% by 12:30 p.m. ET Tuesday despite beating third-quarter earnings expectations and raising 2026 guidance. Adjusted earnings were $2.59 per share against an expected $2.53, and sales grew 5.9%. However, adjusted profit fell 7.5% and GAAP profit dropped to $0.09 per share, down 96%, due to a one-time charge for the proposed talc litigation resolution and deals involving Firefly Bio and Sail Biomedicines. Free cash flow rose more than 6% to $15.1 billion, and the company now expects 2026 sales to grow 7.4% to $101.2 billion with adjusted earnings of about $11.10 per share. The author argues the stock's valuation of more than 22x adjusted earnings and nearly 29x free cash flow is too high for roughly 7% growth, and rates it a 'sell.'
- Johnson & Johnson Q3 2026 Earnings Call Summary
- 2 High-Flying Dividend Stocks to Buy and Hold for a Decade
The article argues healthcare is rebounding in 2026, with Merck (MRK) shares up 39% and AbbVie (ABBV) up 24% year to date, versus about 12% for the S&P 500. Merck's second-quarter revenue rose 5% to $16.6 billion, beating estimates, with Keytruda sales of $8.4 billion, though Keytruda may lose patent exclusivity by 2028. AbbVie's second-quarter revenue grew 10.2% to nearly $17 billion and adjusted EPS rose 22.9% to $3.65, driven by Skyrizi and Rinvoq sales growing about 24%. AbbVie is on a streak of 54 consecutive annual dividend increases, including its time as part of Abbott Laboratories, qualifying it as a Dividend King. The author concludes both are attractive long-term holdings based on financial results, pipelines, and dividends.
Related markets
Latest news
- Vanguard's Tech ETF Is About 10% Below Its Record. History Says What Usually Comes Next.
VGT closed at a record $129.80 on Oct. 6 and was around $117 at writing, about 10% lower, after a roughly 4% fall on Friday. The author counts 19 closes at least 10% below a prior record since January 2004; in the 17 cases with a year of follow-up, the fund rose 14 times, with a median gain of around 21%, though these drops did not improve the odds versus its usual 12-month results. The three losing years all followed drops of over 20%, the worst being November 2007, when the fund was about 44% lower a year later. With the Fed holding its rate range at 3.75% to 4% after raising it on Sept. 16, and the fund trading around 33 times earnings, the author would hold rather than sell, but does not see this drop as a bargain yet.
- How Much Can People Still Save After Covering Living Costs?
At the socio-economic session on the morning of 31/10, delegate Trịnh Xuân An (Đồng Nai) argued that people care how much they can save after covering living costs, while businesses need resources left after costs and interest to invest in technology. Average employee income rose about 9% in the first 9 months, but with CPI up 4.52%, real income grew only about 4.3%. He proposed making real lending rate cuts a key policy priority and making preferential rates and fees transparent. Delegate Nguyễn Cao Sơn (Phú Thọ) asked for extended debt restructuring and keeping debt groups unchanged until the end of 2027 for businesses hit by market swings, and for consideration of cutting the gasoline special consumption tax to 0%. Deputy PM Nguyễn Văn Thắng asked EVN to prepare a plan to lower average retail electricity prices from 1/11/2026 to 31/3/2027.
- National Assembly Delegate: Construction Contractors 'The More They Work, The More They Lose'
Delegate Trần Thị Vân said published unit prices for some public investment projects are well below market prices, putting contractors at risk of losses, delaying projects and blocking capital disbursement. Delegate Nguyễn Cao Sơn said labor, material and fuel costs have surged as many major projects run at once, with demand for filling sand exceeding 600 million m3 against supply of about 394.5 million m3. Some firms pay workers 900,000 to 1 million VND, versus a standard rate of 300,000–400,000 VND per workday. Delegates proposed risk-sharing for contracts signed before July 1, lower lending rates, debt restructuring, keeping debt groups unchanged until the end of 2027, and recapitalizing four state-owned banks.
- Apple Retakes Top Spot From Nvidia With Market Value Above $5,000 Billion
Apple regained the title of world's most valuable company from Nvidia in trading on October 30: Apple shares fell 1.2% to a market cap of $5,030 billion, while Nvidia dropped 4.2% to $4,930 billion. The sell-off followed disappointing earnings from Intel and Amazon and results below expectations from Alphabet and Meta, fuelling worries about returns on AI spending. Apple has gained 27% in 2026, more than double Nvidia's gain, while it keeps tight control over capital spending, and its free cash flow is projected to rise 38% to $142 billion in fiscal 2026. The Nasdaq 100 fell 6.7% in October, its worst month since March 2025, and Intel shares slid more than 45%.
- Bucking Layoff Trend, Google Adds 10,000 Employees
Google added about 10,000 employees over the past six months, bringing its total workforce to 204,757 by the end of September, while Meta and Microsoft were cutting costs and staff. According to its third-quarter earnings report, the growth came mainly from internal hiring and acquisitions, including the purchase of cybersecurity firm Wiz on March 11, which added about 2,000 staff. The hiring comes as quarterly revenue rose 25% year on year, following a major layoff of about 12,000 positions in January 2023. Experts say whether Google sustains this hiring will depend on market conditions, business demand and progress in artificial intelligence.
- Intel Drags Down CPU Rivals. Is it a Buying Opportunity for AMD and Arm?
Intel's third-quarter results triggered a chip-sector sell-off: its shares plunged 29%, their worst day since 1974, and the VanEck Semiconductor ETF fell 7%. Although revenue rose 21% to $16.5 billion, fourth-quarter guidance of $15–16 billion fell short of the $17.1 billion consensus, as a PC slowdown triggered by memory shortages weighed on revenue and margins. AMD and Arm also fell about 11% and 10%, partly on sentiment, though the article notes AMD has less PC exposure than Intel and posted 107% data center growth in the second quarter. The article suggests investors may want to wait for sentiment to stabilize before buying these CPU stocks.
Get the briefing on Telegram or Zalo
Join the Upside Telegram channel or Zalo group for the Vietnam stocks and gold briefing at 8:00 and 19:00 (Vietnam time) on trading days, plus a weekly wrap on Saturday morning.